Published in Women's Health Weekly, May 31st, 2001
Nearly 80% of the patients studied had complete clearance of their warts, and 95% had greater than 50% reduction in the size of their lesions.
Aldara is the first in a new class of drugs called immune response modifiers (IRMs) that demonstrate both antiviral and antitumor activity. IRMs act by stimulating the patient's own immune system to fight the virus and therefore resolve the warts.
Aldara was approved by the U.S. Food and Drug Administration...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly